文献速递腹部技术与安全US

六氟化硫与全氟丁烷超声造影:诊断肝细胞癌的LI-RADS

Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane: LI-RADS for Diagnosing Hepatocellular Carcinoma.
PubMed 文献 · Radiology · 2023-01-01

多中心前瞻性研究纳入375例高危患者共424个观察病灶,同日行六氟化硫(SHF)与全氟丁烷(PFB)超声造影。基于LI-RADS v2017,SHF与PFB诊断HCC的敏感度(60% vs 58%)和特异度(96% vs 95%)无显著差异;纳入Kupffer期表现的改良PFB算法敏感度提高(80% vs 58%,P<.001),特异度无显著下降(92% vs 95%,P=.73)。

要点

  • 基于LI-RADS v2017,SHF与PFB诊断HCC特异度高(96% vs 95%)、敏感度较低(60% vs 58%)。
  • 改良PFB算法纳入Kupffer期表现后敏感度提高至80%,特异度92%无显著下降。
  • 改良PFB对≥10 mm无环状动脉期高增强病灶,无廓清伴Kupffer期缺损者由LR-4升为LR-5。

核心结论

  • 基于CEUS LI-RADS v2017,SHF与PFB均获得高特异度和相对较低敏感度;纳入Kupffer期表现后,PFB敏感度提高且特异度无显著下降。

研究设计与样本

  • 多中心前瞻性研究,2021年6月至2021年12月纳入HCC高危患者375例(平均年龄56岁±11,男318例、女57例),共424个观察病灶(HCC 345个、非HCC恶性肿瘤40个、良性病灶39个)。

关键影像表现/征象

  • 每个病灶同日先后行SHF增强US和PFB增强US,分别按LI-RADS SHF、LI-RADS PFB和改良PFB三种算法分类。
  • 改良PFB算法:≥10 mm且无环状动脉期高增强的病灶,若无廓清并伴Kupffer期缺损,由LR-4升为LR-5。
  • 改良PFB算法:若出现早期廓清伴轻度Kupffer期缺损,由LR-M重新归为LR-5。

诊断标准与关键数值

  • 参考标准为病理确诊或复合标准(典型CT或MRI特征,或1年大小稳定和/或缩小)。
  • LI-RADS SHF诊断HCC(LR-5)敏感度58%、特异度95%。
  • LI-RADS PFB诊断HCC(LR-5)敏感度60%、特异度96%,与SHF相比敏感度P=.41、特异度P>.99。
  • 改良PFB诊断HCC(LR-5)敏感度80%、特异度92%,与SHF相比敏感度P<.001、特异度P=.73。

临床应用与阅片要点

  • 对高危患者行CEUS时,可依据LI-RADS v2017分别解读SHF与PFB图像,两者诊断HCC特异度均高。
  • 采用PFB时,可结合Kupffer期表现:无廓清伴Kupffer期缺损可将LR-4升为LR-5,早期廓清伴轻度Kupffer期缺损可将LR-M归为LR-5。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Liver Imaging Reporting and Data System (LI-RADS) was designed for contrast-enhanced US (CEUS) with pure blood pool agents to diagnose hepatocellularfcarcinoma (HCC), such as sulfur hexafluoride (SHF), but Kupffer-cell agents, such as perfluorobutane (PFB), allow additional lesion characterization in the Kupffer phase yet remain unaddressed. Purpose To compare the diagnostic performance of three algorithms for HCC diagnosis: two algorithms based on CEUS LI-RADS version 2017 for both SHF and PFB and a modified algorithm incorporating Kupffer-phase findings for PFB. Materials and Methods This multicenter prospective study enrolled high-risk patients for HCC from June 2021 to December 2021. Each participant underwent same-day SHF-enhanced US followed by PFB-enhanced US. Each liver observation was assigned three LI-RADS categories according to each algorithm: LI-RADS SHF, LI-RADS PFB, and modified PFB. For modified PFB, observations at least 10 mm with nonrim arterial phase hyperenhancement were upgraded LR-4 to LR-5 if there was no washout with a Kupffer defect and were reassigned LR-M to LR-5 if there was early washout with mild Kupffer defect. The reference standard was pathologic confirmation or composite (typical CT or MRI features, or 1-year size stability and/or reduction). Diagnostic metrics of LR-5 for HCC using the three algorithms were calculated and compared using the McNemar test. Results Overall, 375 patients (mean age, 56 years ± 11 [SD]; 318 male patients, 57 female patients) with 424 observations (345 HCCs, 40 non-HCC malignancies, 39 benign lesions) were enrolled. PFB and SHF both using LI-RADS showed no significant difference in sensitivity (60% vs 58%; P = .41) and specificity (96% vs 95%; P > .99). The modified algorithm with PFB had increased sensitivity (80% vs 58%; P < .001) and a nonsignificant decrease in specificity (92% vs 95%; P = .73) compared with LI-RADS SHF. Conclusion Based on CEUS LI-RADS version 2017, both SHF and PFB achieved high specificity and relatively low sensitivity for HCC diagnosis. When incorporating Kupffer-phase findings, PFB had higher sensitivity without loss of specificity. Chinese Clinical Trial Registry no. ChiCTR2100047035 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Kim in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Li L, Zou X, Zheng W, et al. Contrast-enhanced US with Sulfur Hexafluoride and Perfluorobutane: LI-RADS for Diagnosing Hepatocellular Carcinoma. Radiology. 2023. PMID: 37642573. doi:10.1148/radiol.230150

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。